Core Viewpoint - The company, Kubo Medical-B (02216), has announced a subscription agreement to issue 105 million shares at a price of HKD 3.11 per share, which represents a premium over the market price on the announcement date [1] Summary by Relevant Categories Subscription Agreement - The company has conditionally agreed to issue a total of 105 million subscription shares [1] - The subscription price of HKD 3.11 per share is approximately 1.3% higher than the closing price of HKD 3.07 on the Hong Kong Stock Exchange on the announcement date [1] - The total number of shares to be issued represents about 16.60% of the enlarged issued share capital of the company, assuming no changes in the issued share capital until completion [1] Financial Implications - The estimated net proceeds from the subscription, after expenses, are approximately HKD 327 million, equating to a net issue price of about HKD 3.106 per share [1] - The net proceeds are intended to fund potential acquisitions in the medical device industry to continuously expand the product portfolio [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 Broncus Holding Corporation （股份代號：2216) 堃 博醫療控股有限公司 （於開曼群島註冊成立的有限公司） 建議根據一般授權發行股份 於2025年10月10日，本公司與各認購方訂立認購協議，據此，本公司已有條件 同意配發及發行，及認購方已有條件同意認購合共105,108,015股認購股份，認 購價為每股認購股份3.11港元。 根據認購事項將予配發及發行的105,108,015股認購股份總數，佔(i)於本公告日 期本公司已發行股本之約19.90%；及(ii)透過發行認購股份擴大的本公司已發行 股本約16.60%（假設自本公告日期起直至完成本公司已發行股本並無變動，惟 因認購事項產生者除外）。認購股份將根據一般授權發行。 認購事項的所得款項總額總計將約為326.9百萬港元，而認購事項的所得款項淨 額總計（扣除 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定 ...

(Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司 (Stock Code: 2216 / 股份代號: 2216) Broncus Holding Corporation 堃博医疗控股有限公司 25 September 2025 Dear Non-registered shareholder(s), Broncus Holding Corporation (the "Company") – Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 20 May 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", the Company is writing to infor ...

Broncus Holding Corporation 堃博医疗控股有限公司 (Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司 ) (Stock Code: 2216 / 股份代號: 2216) 25 September 2025 Dear registered shareholder(s), Broncus Holding Corporation (the "Company") – Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (Note 1) With reference to the notification letter dated 20 May 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications ", the Company is writing ...

Financial Performance - Revenue for the six months ended June 30, 2025, was $1,652,000, a decrease of 55.4% compared to $3,704,000 for the same period in 2024[11]. - Gross profit for the same period was $1,214,000, down 58.9% from $2,954,000 year-over-year[11]. - The net loss for the period was $(7,792,000), a slight improvement of 1.9% compared to $(7,943,000) in the previous year[11]. - Revenue for the six months ended June 30, 2025, was approximately $1.7 million, a decrease of about 55.4% compared to $3.7 million for the same period in 2024[77]. - Gross profit for the same period was approximately $1.2 million, down about 58.9% from $3.0 million in the previous year, resulting in a gross margin of approximately 73.5%[79]. - Other income and gains increased to approximately $4.5 million, up about $1.1 million from $3.4 million in the previous year, primarily due to increased government subsidies[80]. - Research and development costs decreased to approximately $4.5 million, down about 31.4% from $6.5 million in the previous year, due to a focus on core product development[84]. - Cash and bank balances totaled approximately $130.8 million as of June 30, 2025, a decrease of about $8.5 million from $139.3 million at the end of 2024[87]. - The capital debt ratio as of June 30, 2025, was 0.03%, a decrease from 0.19% at the end of 2024[90]. - Sales and distribution expenses were approximately $3.3 million, a decrease of about 11.9% compared to the previous year[81]. - The adjusted net loss for the six months ended June 30, 2025, was $6,956,000, compared to $7,832,000 for the same period in 2024, reflecting a decrease of approximately 11.1%[97]. - Total employee costs for the reporting period were approximately $6.01 million, down from $7.86 million in the same period of 2024, indicating a reduction of about 23.5%[103]. - The company reported a net loss of $7,792,000 for the six months ended June 30, 2025, slightly improved from a net loss of $7,943,000 in the same period of 2024[97]. Product Development and Innovation - The company’s core product, BroncAblate®智衡®, received approval from the National Medical Products Administration (NMPA) for market launch in China, marking a significant innovation in lung cancer treatment[12]. - As of July 2025, BroncAblate®智衡® has been clinically applied in multiple top medical centers across the country, demonstrating significant clinical efficacy[13]. - InterVapor® has been trialed in over 200 hospitals in China, with more than 500 clinical applications reported, receiving positive feedback from both doctors and patients[14]. - The company is advancing its clinical trials for the TLD ablation system, with 109 subjects enrolled as of June 30, 2025, showing general improvement in patient clinical performance[17]. - The company is actively promoting innovative products in the respiratory intervention field, with a focus on commercializing and expanding clinical applications[16]. - The lung imaging processing software BroncQCT® received approval from the Zhejiang Provincial Drug Administration for market entry in China in March 2025, significantly enhancing doctors' efficiency in interpreting lung CT images[18]. - The LungPro® augmented reality optical lung navigation system was showcased at the 5th International Sublobar Conference and Bronchoscopic Ablation Summit in Paris, highlighting its clinical advancements and strong feedback from experts[20]. - The company established a comprehensive interventional respiratory disease treatment platform, integrating navigation, diagnosis, and treatment, addressing unmet clinical needs in the rapidly growing interventional pulmonology market[24]. - The company showcased its one-stop respiratory intervention innovation solution at the 2025 CMEF in Shanghai, covering the entire process from precise positioning to effective treatment[21]. - The company is committed to global strategic expansion, actively promoting its products and technologies in international markets[20]. Market Presence and Regulatory Approvals - As of June 30, 2025, the company holds 69 overseas registration certificates, including 4 CE certificates and 7 FDA certificates, indicating successful market access efforts[23]. - The company introduced the BroncAblate®智衡® lung radiofrequency ablation system at multiple academic forums, receiving high praise for its clinical value in minimally invasive lung treatment[23]. - The company is focusing on the commercialization of interventional treatment products, with ongoing clinical trials and product development aimed at filling domestic market gaps[63]. - The respiratory intervention market is evolving towards precision treatment, necessitating a repositioning of navigation products to enhance their clinical value[63]. - The company aims to expand its market space and accelerate the development of more product pipelines to support sustainable growth and value creation[71]. - The company has received government subsidies totaling $1.7 million during the reporting period, compared to $0.1 million as of June 30, 2024[72]. - The company is actively promoting the inclusion of innovative products in China's medical insurance, with InterVapor® already covered in some provinces[69]. Clinical Trials and Research - The company is actively conducting post-market clinical studies for InterVapor® across over 30 hospitals in China, aiming to gather high-quality evidence for COPD treatment[38]. - The TLD radiofrequency ablation energy system, developed in collaboration with Sichuan University, has initiated a clinical trial involving 189 moderate to severe COPD patients across over 20 centers, with more than 100 participants enrolled as of June 30, 2025[39]. - The BTVA technique, associated with the InterVapor® system, has been included in the GOLD guidelines for COPD treatment for seven consecutive years, highlighting its significance in improving lung function and quality of life for patients[36]. - The TLD system's clinical trial is expected to complete all follow-ups by 2026, with data release planned post-trial completion[39]. Corporate Governance and Compliance - The company has established compliance policies to ensure adherence to applicable laws and regulations, with no significant non-compliance events reported during the period[141]. - The company has adopted corporate governance practices based on the principles outlined in the Corporate Governance Code, ensuring compliance with applicable provisions[142]. - The company will continue to review and monitor its corporate governance practices to maintain high standards[144]. Shareholder Information and Equity Plans - The company did not recommend the payment of an interim dividend for the reporting period, consistent with the previous year[98]. - The company has adopted two equity incentive plans: a stock option plan and a restricted share unit plan[114]. - The total number of securities available for issuance under the stock option plan is 4,096,960 shares, approximately 0.78% of the total issued shares[115]. - The company has a stock option plan that allows for the granting of options to eligible participants, including senior executives and employees, with a maximum allocation of 1% of issued shares[119]. - The company has a total of 2,658,588 shares in BRS Biomedical Limited, with 2,160,000 shares attributed to Mr. Zi under a restricted share unit plan[117]. - The company has not granted any rewards under the Restricted Share Unit Plan during the reporting period, with the number of available rewards remaining at 51,922,566 shares[123].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | ...

堃博医疗-B(02216)发布截至2025年6月30日止6个月中期业绩，集团收入165.2万美元，同比减少55.4%; 净亏损779.2万美元，同比收窄1.9%;毛利121.4万美元，同比减少58.9%。 ...

Core Viewpoint - Kubo Medical-B (02216) reported a significant decline in revenue for the six months ending June 30, 2025, indicating challenges in the business environment [1] Financial Performance - The company's revenue was $1.652 million, representing a year-on-year decrease of 55.4% [1] - Net loss for the period was $7.792 million, which is a slight improvement of 1.9% compared to the previous year [1] - Gross profit stood at $1.214 million, down 58.9% year-on-year [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Broncus Holding Corporation 堃 博醫療控股有限公司 （於開曼群島註冊成立的有限公司） 堃博醫療控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公 司及其附屬公司（統稱「本集團」或「我們」）截至2025年6月30日止六個月（「報告 期」）之未經審核綜合中期業績，連同截至2024年6月30日止六個月之未經審核比 較數字。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至 | 截至 | | | | 2025年 | 2024年 | | | | 6月30日 | 6月30日 | | | | 止六個月 | 止六個月 | 同比變動 | | | 千美元 | 千美元 | | | 收入 | 1,652 | 3,704 | -55.4% | | 毛利 | 1,214 | 2,954 | -58.9% | | 期內虧損 | (7,79 ...